Status:
COMPLETED
Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia
Lead Sponsor:
Children's Cancer Hospital Egypt 57357
Conditions:
Cardiotoxicity
Acute Myeloid Leukemia in Children
Eligibility:
All Genders
1-18 years
Phase:
PHASE3
Brief Summary
Prevention and early detection of chemotherapy-induced cardiotoxicity in children with bone tumors and Acute Myeloid Leukemia by giving capoten
Detailed Description
background and rationale: Developing countries bear the greatest burden of childhood cancers as over 90% of the world's children live in these countries. More effective treatment protocols have marked...
Eligibility Criteria
Inclusion
- All Acute Myeloid Leukemia and Bone Tumors patients (Osteosarcoma and Ewing's Sarcoma) who didn't receive chemotherapy will be included in the study.
- Written Informed Consent from parents/guardian
Exclusion
- Patients who received chemotherapy before starting of the study
- Patients with history of cardiac impairment, (existing or congenital heart disease).
- Patients who show intolerance or contra-indications to ACE-I.
- Patients developing acute (\< 2 weeks) cardiotoxicity after the first high-dose chemotherapy (HDC) course.
Key Trial Info
Start Date :
November 14 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2021
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT03389724
Start Date
November 14 2017
End Date
November 1 2021
Last Update
November 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Cancer Hospital Egypt 57357 Cairo, Egypt
Cairo, Egypt